Establishing a Diagnosis of Lung Cancer Through a Fluid Biopsy
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Carcinoma
- Sponsor
- University of Southern California
- Enrollment
- 51
- Locations
- 2
- Primary Endpoint
- Clinical diagnosis of lung cancer
- Status
- Terminated
- Last Updated
- 7 months ago
Overview
Brief Summary
This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.
Detailed Description
PRIMARY OBJECTIVE: I. To estimate the sensitivity and specificity of the fluid biopsy in establishing a diagnosis of bronchogenic carcinoma. SECONDARY OBJECTIVES: I. To determine the accuracy of determination of the histologic subtype of bronchogenic lung cancer. II. To determine the relative contribution of cell based high definition circulating tumor cell assay (HD-CTC) and imaging mass cytometry (IMC) and plasma based circulating tumor deoxyribonucleic acid (ctDNA) assays in determination of diagnosis and histologic subtype. OUTLINE: Patients undergo collection of blood samples on day 1 for analysis via high definition (HD)-single cell analysis (SCA) fluid biopsy. Medical charts of patients are reviewed at 3 months post-biopsy or computed tomography (CT) screening. After completion of study, patients are followed for up to 1 year.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Scheduled to undergo a diagnostic biopsy for possible lung cancer or
- •Completed a diagnostic lung cancer biopsy in the prior 2 weeks and has not yet undergone treatment or
- •Planning or completed in the last 2 weeks a CT lung cancer screen
- •Ability to understand and the willingness to sign a written informed consent
Exclusion Criteria
- •Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study
- •Known other solid tumor malignancy other than lung cancer requiring ongoing active treatment
Outcomes
Primary Outcomes
Clinical diagnosis of lung cancer
Time Frame: Within 90 days of tissue biopsy
Descriptive statistics including sensitivity, specificity, positive, and negative predictive value will be tabulated.